메뉴 건너뛰기




Volumn 1102, Issue , 2014, Pages 45-69

Advances in adjuvant therapy: Potential for prognostic and predictive biomarkers

Author keywords

Adjuvant; BRAF; CTLA 4; Debrafenib; IFN ; Interferon; Ipilimumab; MEK; Melanoma; Trametinib; Vemurafenib

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; TUMOR MARKER;

EID: 84891792788     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-727-3_4     Document Type: Article
Times cited : (3)

References (60)
  • 2
    • 84869210903 scopus 로고    scopus 로고
    • How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?
    • Tarhini AA, Kirkwood JM (2012) How much of a good thing? What duration for interferon Alfa-2b adjuvant therapy? J Clin Oncol 30(31):3773-3776
    • (2012) J Clin Oncol , vol.30 , Issue.31 , pp. 3773-3776
    • Tarhini, A.A.1    Kirkwood, J.M.2
  • 3
    • 74949143594 scopus 로고    scopus 로고
    • Final version of 2009 AJCC melanoma staging and classification
    • Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199-6206
    • (2009) J Clin Oncol , vol.27 , Issue.36 , pp. 6199-6206
    • Balch, C.M.1    Gershenwald, J.E.2    Soong, S.J.3
  • 4
    • 58149375115 scopus 로고    scopus 로고
    • Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: A multicenter study in 388 patients with positive sentinel nodes
    • van Akkooi AC, Nowecki ZI, Voit C et al (2008) Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: A multicenter study in 388 patients with positive sentinel nodes. Ann Surg 248(6): 949-955
    • (2008) Ann Surg , vol.248 , Issue.6 , pp. 949-955
    • Van Akkooi, A.C.1    Nowecki, Z.I.2    Voit, C.3
  • 5
    • 53549087527 scopus 로고    scopus 로고
    • How tumors escape mass destruction
    • Stewart TJ, Abrams SI (2008) How tumors escape mass destruction. Oncogene 27:5894-5903
    • (2008) Oncogene , vol.27 , pp. 5894-5903
    • Stewart, T.J.1    Abrams, S.I.2
  • 6
    • 0029774810 scopus 로고    scopus 로고
    • Interleukin 10 production by human melanoma
    • Sato T, McCue P, Masuoka K et al (1996) Interleukin 10 production by human melanoma. Clin Cancer Res 2:1383-1390
    • (1996) Clin Cancer Res , vol.2 , pp. 1383-1390
    • Sato, T.1    McCue, P.2    Masuoka, K.3
  • 7
    • 0030724702 scopus 로고    scopus 로고
    • Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
    • Enk AH, Jonuleit H, Saloga J, Knop J (1997) Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73:309-316
    • (1997) Int J Cancer , vol.73 , pp. 309-316
    • Enk, A.H.1    Jonuleit, H.2    Saloga, J.3    Knop, J.4
  • 8
    • 0033047725 scopus 로고    scopus 로고
    • Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions
    • Kirkwood JM, Farkas DL, Chakraborty A et al (1999) Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med 5(1):11-20
    • (1999) Mol Med , vol.5 , Issue.1 , pp. 11-20
    • Kirkwood, J.M.1    Farkas, D.L.2    Chakraborty, A.3
  • 9
    • 33745989541 scopus 로고    scopus 로고
    • Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses
    • Moschos SJ, Edington HD, Land SR et al (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24(19):3164-3171
    • (2006) J Clin Oncol , vol.24 , Issue.19 , pp. 3164-3171
    • Moschos, S.J.1    Edington, H.D.2    Land, S.R.3
  • 10
    • 79953087601 scopus 로고    scopus 로고
    • Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
    • Gajewski TF, Fuertes M, Spaapen R et al (2011) Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 23(2):286-292
    • (2011) Curr Opin Immunol , vol.23 , Issue.2 , pp. 286-292
    • Gajewski, T.F.1    Fuertes, M.2    Spaapen, R.3
  • 11
    • 34249709048 scopus 로고    scopus 로고
    • Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma
    • Critchley-Thorne RJ, Yan N, Nacu S et al (2007) Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 4(5): E176
    • (2007) PLoS Med , vol.4 , Issue.5
    • Critchley-Thorne, R.J.1    Yan, N.2    Nacu, S.3
  • 12
    • 79955561959 scopus 로고    scopus 로고
    • Interferon signaling patterns in peripheral blood lymphocytes
    • may predict clinical outcome after high-dose interferon therapy in melanoma patients
    • Simons DL, Lee G, Kirkwood JM, Lee PP (2011) Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med 9:52
    • (2011) J Transl Med , vol.9 , pp. 52
    • Simons, D.L.1    Lee, G.2    Kirkwood, J.M.3    Lee, P.P.4
  • 13
    • 0030030347 scopus 로고    scopus 로고
    • Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The eastern cooperative oncology group trial est 1684
    • Kirkwood JM, Strawderman MH, Ernstoff MS et al (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17
    • (1996) J Clin Oncol , vol.14 , pp. 7-17
    • Kirkwood, J.M.1    Strawderman, M.H.2    Ernstoff, M.S.3
  • 14
    • 1842533233 scopus 로고    scopus 로고
    • A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma
    • Kirkwood JM, Manola J, Ibrahim J et al (2004) A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10(5):1670-1677
    • (2004) Clin Cancer Res , vol.10 , Issue.5 , pp. 1670-1677
    • Kirkwood, J.M.1    Manola, J.2    Ibrahim, J.3
  • 15
    • 0034088027 scopus 로고    scopus 로고
    • High-and low-dose interferon alfa-2b in high-risk melanoma: Fi rst analysis of intergroup trial E1690/S9111/C9190
    • Kirkwood JM, Ibrahim JG, Sondak VK et al (2000) High-and low-dose interferon alfa-2b in high-risk melanoma: Fi rst analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18(12):2444-2458
    • (2000) J Clin Oncol , vol.18 , Issue.12 , pp. 2444-2458
    • Kirkwood, J.M.1    Ibrahim, J.G.2    Sondak, V.K.3
  • 16
    • 0035339880 scopus 로고    scopus 로고
    • High-dose interferon alfa-2b signifi -cantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/ S9512/C509801
    • Kirkwood JM, Ibrahim JG, Sosman JA et al (2001) High-dose interferon alfa-2b signifi -cantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/ S9512/C509801. J Clin Oncol 19(9): 2370-2380
    • (2001) J Clin Oncol , vol.19 , Issue.9 , pp. 2370-2380
    • Kirkwood, J.M.1    Ibrahim, J.G.2    Sosman, J.A.3
  • 17
    • 0028872887 scopus 로고
    • Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma
    • Creagan ET, Dalton RJ, Ahmann DL et al (1995) Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13(11):2776-2783
    • (1995) J Clin Oncol , vol.13 , Issue.11 , pp. 2776-2783
    • Creagan, E.T.1    Dalton, R.J.2    Ahmann, D.L.3
  • 18
    • 0035281923 scopus 로고    scopus 로고
    • High-dose interferon alfa-2b does not diminish antibody response to gm2 vaccination in patients with resected melanoma: Results of the multicenter eastern cooperative oncology group phase ii trial e2696
    • Kirkwood JM, Ibrahim J, Lawson DH et al (2001) High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 19(5):1430-1436
    • (2001) J Clin Oncol , vol.19 , Issue.5 , pp. 1430-1436
    • Kirkwood, J.M.1    Ibrahim, J.2    Lawson, D.H.3
  • 19
    • 84859460536 scopus 로고    scopus 로고
    • Intensifi ed high-dose intravenous interferon alpha 2b (ifna2b) for adjuvant treatment of stage iii melanoma: A randomized phase iii italian melanoma intergroup IMI) trial [isrctn75125874
    • for Italian Melanoma Intergroup (IMI suppl):abstr 8506
    • Chiarion-Sileni V, Guida M, Romanini A et al for Italian Melanoma Intergroup (IMI) (2011) Intensifi ed high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]. J Clin Oncol 29(suppl):abstr 8506
    • (2011) J Clin Oncol , vol.29
    • Chiarion-Sileni, V.1    Guida, M.2    Romanini, A.3
  • 20
    • 25844465690 scopus 로고    scopus 로고
    • Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial
    • Eggermont AM, Suciu S, MacKie R et al (2005) Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial. Lancet 366(9492):1189-1196
    • (2005) Lancet , vol.366 , Issue.9492 , pp. 1189-1196
    • Eggermont, A.M.1    Suciu, S.2    MacKie, R.3
  • 21
    • 77952469658 scopus 로고    scopus 로고
    • Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: Prognostic significance of autoantibodies -EORTC 18991
    • Bouwhuis MG, Suciu S, Testori A et al (2010) Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: Prognostic significance of autoantibodies -EORTC 18991. J Clin Oncol 28(14): 2460-2466
    • (2010) J Clin Oncol , vol.28 , Issue.14 , pp. 2460-2466
    • Bouwhuis, M.G.1    Suciu, S.2    Testori, A.3
  • 22
    • 79151485188 scopus 로고    scopus 로고
    • Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (nordic ifn trial): A randomised phase 3 trial
    • Hansson J, Aamdal S, Bastholt L et al (2011) Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): A randomised phase 3 trial. Lancet Oncol 12(2):144-152
    • (2011) Lancet Oncol , vol.12 , Issue.2 , pp. 144-152
    • Hansson, J.1    Aamdal, S.2    Bastholt, L.3
  • 23
    • 7144264391 scopus 로고    scopus 로고
    • Adjuvant interferon alfa-2a treatment in resected primary stage ii cutaneous melanoma austrian malignant melanoma cooperative group
    • Pehamberger H, Soyer HP, Steiner A et al (1998) Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 16(4):1425-1429
    • (1998) J Clin Oncol , vol.16 , Issue.4 , pp. 1425-1429
    • Pehamberger, H.1    Soyer, H.P.2    Steiner, A.3
  • 24
    • 7144228601 scopus 로고    scopus 로고
    • Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases french cooperative group on melanoma
    • Grob JJ, Dreno B, de la Salmonière P et al (1998) Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351(9120): 1905-1910
    • (1998) Lancet , vol.351 , Issue.9120 , pp. 1905-1910
    • Grob, J.J.1    Dreno, B.2    De La Salmonière, P.3
  • 25
    • 0035883950 scopus 로고    scopus 로고
    • Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial
    • Cascinelli N, Belli F, MacKie RM et al (2001) Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet 358(9285):866-869
    • (2001) Lancet , vol.358 , Issue.9285 , pp. 866-869
    • Cascinelli, N.1    Belli, F.2    MacKie, R.M.3
  • 26
    • 0035805053 scopus 로고    scopus 로고
    • Adjuvant interferon alpha 2b in high risk melanoma - The Scottish study
    • Cameron DA, Cornbleet MC, Mackie RM et al (2001) Adjuvant interferon alpha 2b in high risk melanoma -the Scottish study. Br J Cancer 84(9):1146-1149
    • (2001) Br J Cancer , vol.84 , Issue.9 , pp. 1146-1149
    • Cameron, D.A.1    Cornbleet, M.C.2    Mackie, R.M.3
  • 27
    • 1642554821 scopus 로고    scopus 로고
    • Final results of the eortc 18871/dkg 80-1 randomised phase iii trial rifn-alpha2b versus rifn-gamma versus iscador m versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis
    • for EORTC Melanoma Group in cooperation with the German Cancer Society (DKG) et al
    • Kleeberg UR, Suciu S, Bröcker EB, for EORTC Melanoma Group in cooperation with the German Cancer Society (DKG) et al (2004) Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 40(3):390-402
    • (2004) Eur J Cancer , vol.40 , Issue.3 , pp. 390-402
    • Kleeberg, U.R.1    Suciu, S.2    Bröcker, E.B.3
  • 28
    • 3242686449 scopus 로고    scopus 로고
    • Adjuvant interferon in high-risk melanoma: The aim high study -united kingdom coordinating committee on cancer research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in highrisk resected malignant melanoma
    • Hancock BW, Wheatley K, Harris S et al (2004) Adjuvant interferon in high-risk melanoma: The AIM HIGH Study -United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in highrisk resected malignant melanoma. J Clin Oncol 22(1):53-61
    • (2004) J Clin Oncol , vol.22 , Issue.1 , pp. 53-61
    • Hancock, B.W.1    Wheatley, K.2    Harris, S.3
  • 29
    • 77649217618 scopus 로고    scopus 로고
    • Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: Results of a randomized phase III DeCOG trial
    • Hauschild A, Weichenthal M, Rass K et al (2010) Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: Results of a randomized phase III DeCOG trial. J Clin Oncol 28(5): 841-846
    • (2010) J Clin Oncol , vol.28 , Issue.5 , pp. 841-846
    • Hauschild, A.1    Weichenthal, M.2    Rass, K.3
  • 30
    • 44849131339 scopus 로고    scopus 로고
    • Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: A prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
    • Garbe C, Radny P, Linse R et al (2008) Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: A prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 19(6):1195-1201
    • (2008) Ann Oncol , vol.19 , Issue.6 , pp. 1195-1201
    • Garbe, C.1    Radny, P.2    Linse, R.3
  • 31
    • 84859386046 scopus 로고    scopus 로고
    • Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate-and high-risk melanoma (Intergroup trial E1697
    • suppl): Abstr 8505
    • Agarwala SS, Lee SJ, Flaherty LE et al (2011) Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate-and high-risk melanoma (Intergroup trial E1697). J Clin Oncol 29(suppl): Abstr 8505
    • (2011) J Clin Oncol , vol.29
    • Agarwala, S.S.1    Lee, S.J.2    Flaherty, L.E.3
  • 32
    • 60849108348 scopus 로고    scopus 로고
    • Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma
    • Pectasides D, Dafni U, Bafaloukos D et al (2009) Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 27(6): 939-944
    • (2009) J Clin Oncol , vol.27 , Issue.6 , pp. 939-944
    • Pectasides, D.1    Dafni, U.2    Bafaloukos, D.3
  • 33
    • 46749103710 scopus 로고    scopus 로고
    • Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Fi nal results of EORTC 18991, a randomised phase III trial
    • Eggermont AM, Suciu S, Santinami M et al (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Fi nal results of EORTC 18991, a randomised phase III trial. Lancet 372(9633):117-126
    • (2008) Lancet , vol.372 , Issue.9633 , pp. 117-126
    • Eggermont, A.M.1    Suciu, S.2    Santinami, M.3
  • 34
    • 84869212118 scopus 로고    scopus 로고
    • Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma
    • Eggermont AM, Suciu S, Testori A et al (2012) Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 30(31):3810-3818
    • (2012) J Clin Oncol , vol.30 , Issue.31 , pp. 3810-3818
    • Eggermont, A.M.1    Suciu, S.2    Testori, A.3
  • 35
    • 0041409703 scopus 로고    scopus 로고
    • Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefi t? A meta-analysis of the randomised trials
    • Wheatley K, Ives N, Hancock B et al (2003) Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefi t? A meta-analysis of the randomised trials. Cancer Treat Rev 29:241-252
    • (2003) Cancer Treat Rev , vol.29 , pp. 241-252
    • Wheatley, K.1    Ives, N.2    Hancock, B.3
  • 36
    • 77950576363 scopus 로고    scopus 로고
    • Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and metaanalysis
    • Mocellin S, Pasquali S, Rossi CR et al (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and metaanalysis. J Natl Cancer Inst 102:493-501
    • (2010) J Natl Cancer Inst , vol.102 , pp. 493-501
    • Mocellin, S.1    Pasquali, S.2    Rossi, C.R.3
  • 37
    • 0036534376 scopus 로고    scopus 로고
    • Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials
    • Lens MB, Dawes M (2002) Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials. J Clin Oncol 20:1818-1825
    • (2002) J Clin Oncol , vol.20 , pp. 1818-1825
    • Lens, M.B.1    Dawes, M.2
  • 38
    • 35649015750 scopus 로고    scopus 로고
    • Interferon-{alpha} as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials
    • abstract 8526
    • Wheatley K, Hancock B, Gore M et al (2007) Interferon-{alpha} as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. J Clin Oncol 25(18 suppl):abstract 8526
    • (2007) J Clin Oncol , vol.25 , Issue.18 SUPPL.
    • Wheatley, K.1    Hancock, B.2    Gore, M.3
  • 39
    • 84891798224 scopus 로고    scopus 로고
    • Active immunization toward the mage-a3 antigen in patients with metastatic melanoma: Fouryear follow-up results from a randomized phase ii study (eortc16032-18031
    • suppl): Abstr 8535
    • Kruit W, Suciu S, Dreno B et al (2011) Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Fouryear follow-up results from a randomized phase II study (EORTC16032-18031). J Clin Oncol 29(suppl): Abstr 8535
    • (2011) J Clin Oncol , vol.29
    • Kruit, W.1    Suciu, S.2    Dreno, B.3
  • 40
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723
    • (2010) N Engl J Med , vol.363 , Issue.8 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 41
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517-2526
    • (2011) N Engl J Med , vol.364 , Issue.26 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3
  • 42
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
    • Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358-342
    • (2012) Lancet , vol.380 , Issue.9839 , pp. 358-342
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3
  • 43
    • 84863673204 scopus 로고    scopus 로고
    • Improved survival with MEK inhibition in BRAF-mutated melanoma
    • Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107-114
    • (2012) N Engl J Med , vol.367 , Issue.2 , pp. 107-114
    • Flaherty, K.T.1    Robert, C.2    Hersey, P.3
  • 44
    • 77954373338 scopus 로고    scopus 로고
    • Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function
    • Boni A, Cogdill AP, Dang P et al (2010) Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70(13):5213-5219
    • (2010) Cancer Res , vol.70 , Issue.13 , pp. 5213-5219
    • Boni, A.1    Cogdill, A.P.2    Dang, P.3
  • 45
    • 84863393623 scopus 로고    scopus 로고
    • Selective BRAF inhibitors induce marked T-cell infi ltration into human metastatic melanoma
    • Wilmott JS, Long GV, Howle JR et al (2012) Selective BRAF inhibitors induce marked T-cell infi ltration into human metastatic melanoma. Clin Cancer Res 18(5):1386-1394
    • (2012) Clin Cancer Res , vol.18 , Issue.5 , pp. 1386-1394
    • Wilmott, J.S.1    Long, G.V.2    Howle, J.R.3
  • 46
    • 80052485771 scopus 로고    scopus 로고
    • Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefi tinib
    • Oxnard GR, Janjigian YY, Arcila ME et al (2011) Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefi tinib. Clin Cancer Res 17(19): 6322-6328
    • (2011) Clin Cancer Res , vol.17 , Issue.19 , pp. 6322-6328
    • Oxnard, G.R.1    Janjigian, Y.Y.2    Arcila, M.E.3
  • 47
    • 65649133474 scopus 로고    scopus 로고
    • Final results of the sunbelt melanoma trial
    • suppl): Abstr 9003
    • McMasters KM, Ross MI, Reintgen DS et al (2008) Final results of the Sunbelt Melanoma Trial. J Clin Oncol 26(suppl): Abstr 9003
    • (2008) J Clin Oncol , vol.26
    • McMasters, K.M.1    Ross, M.I.2    Reintgen, D.S.3
  • 48
    • 84857038232 scopus 로고    scopus 로고
    • Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?
    • Eggermont AM, Spatz A, Lazar V, Robert C (2012) Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? Curr Opin Oncol 24(2):137-140
    • (2012) Curr Opin Oncol , vol.24 , Issue.2 , pp. 137-140
    • Eggermont, A.M.1    Spatz, A.2    Lazar, V.3    Robert, C.4
  • 49
    • 84866945192 scopus 로고    scopus 로고
    • FC13 DERMA Phase III trial of MAGE-A3 immunotherapy as adjuvant treatment in stage III melanoma: MAGE-A3 gene expression frequency and baseline demographics
    • Trefzer U, Jouary T, Robert C et al (2010) FC13 DERMA Phase III trial of MAGE-A3 immunotherapy as adjuvant treatment in stage III melanoma: MAGE-A3 gene expression frequency and baseline demographics. Melanoma Res 20:e34-e35
    • (2010) Melanoma Res , vol.20
    • Trefzer, U.1    Jouary, T.2    Robert, C.3
  • 50
    • 0023888654 scopus 로고
    • Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells
    • Atkins MB, Mier JW, Parkinson DR et al (1988) Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318(24):1557-1563
    • (1988) N Engl J Med , vol.318 , Issue.24 , pp. 1557-1563
    • Atkins, M.B.1    Mier, J.W.2    Parkinson, D.R.3
  • 51
    • 32644454916 scopus 로고    scopus 로고
    • Prognostic significance of autoimmunity during treatment of melanoma with interferon
    • Gogas H, Ioannovich J, Dafni U et al (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354(7):709-718
    • (2006) N Engl J Med , vol.354 , Issue.7 , pp. 709-718
    • Gogas, H.1    Ioannovich, J.2    Dafni, U.3
  • 52
    • 58149396712 scopus 로고    scopus 로고
    • Prognostic significance of serum s100b protein in high-risk surgically resected melanoma patients participating in intergroup trial ecog 1694
    • Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM (2009) Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 27(1):38-44
    • (2009) J Clin Oncol , vol.27 , Issue.1 , pp. 38-44
    • Tarhini, A.A.1    Stuckert, J.2    Lee, S.3    Sander, C.4    Kirkwood, J.M.5
  • 54
  • 55
    • 58149396712 scopus 로고    scopus 로고
    • Prognostic significance of serum s100b protein in high-risk surgically resected melanoma patients participating in intergroup trial ecog 1694
    • Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM (2009) Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 27(1):38-44
    • (2009) J Clin Oncol , vol.27 , Issue.1 , pp. 38-44
    • Tarhini, A.A.1    Stuckert, J.2    Lee, S.3    Sander, C.4    Kirkwood, J.M.5
  • 56
    • 37049002728 scopus 로고    scopus 로고
    • Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696
    • ASCO Annual Meeting Proceedings Part I 25, no. 18S (June 20 Supplement
    • Stuckert JJ, Tarhini AA, Lee S et al (2007) Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I, vol 25, no. 18S (June 20 Supplement): 8506
    • (2007) J Clin Oncol , vol.2007 , pp. 8506
    • Stuckert, J.J.1    Tarhini, A.A.2    Lee, S.3
  • 57
    • 79251599240 scopus 로고    scopus 로고
    • Prognostic value of serial blood s100b determinations in stage iib-iii melanoma patients: A corollary study to eortc trial 18952
    • Bouwhuis MG, Suciu S, Kruit W et al (2011) Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: A corollary study to EORTC trial 18952. Eur J Cancer 47(3):361-368
    • (2011) Eur J Cancer , vol.47 , Issue.3 , pp. 361-368
    • Bouwhuis, M.G.1    Suciu, S.2    Kruit, W.3
  • 58
    • 67449138506 scopus 로고    scopus 로고
    • Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon
    • Bouwhuis MG, Suciu S, Collette S et al (2009) Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 101(12):869-877
    • (2009) J Natl Cancer Inst , vol.101 , Issue.12 , pp. 869-877
    • Bouwhuis, M.G.1    Suciu, S.2    Collette, S.3
  • 59
    • 79960701540 scopus 로고    scopus 로고
    • Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α EORTC 18952) and prognostic value on treatment outcome
    • Bouwhuis MG, Collette S, Suciu S et al (2011) Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18952) and prognostic value on treatment outcome. Melanoma Res 21(4):344-351
    • (2011) Melanoma Res , vol.21 , Issue.4 , pp. 344-351
    • Bouwhuis, M.G.1    Collette, S.2    Suciu, S.3
  • 60
    • 77952469658 scopus 로고    scopus 로고
    • Phase III trial comparing adjuvant treatment with pegylated interferon alfa-2b versus observation: Prognostic significance of autoantibodies -eortc 18991
    • Bouwhuis MG, Suciu S, Testori A et al (2010) Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: Prognostic significance of autoantibodies -EORTC 18991. J Clin Oncol 28(14): 2460-2466
    • (2010) J Clin Oncol , vol.28 , Issue.14 , pp. 2460-2466
    • Bouwhuis, M.G.1    Suciu, S.2    Testori, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.